Usefulness of Controlled Aliasing in Parallel Imaging Results in Higher Acceleration in Gadoxetic Acid–Enhanced Liver Magnetic Resonance Imaging to Clarify the Hepatic Arterial Phase

PurposeWe aimed to determine whether the controlled aliasing in parallel imaging results in higher acceleration (CAIPIRINHA) technique could improve the image quality of the hepatic arterial phase of gadoxetic acid–enhanced liver magnetic resonance (MR) imaging. Materials and MethodsA total of 320 patients underwent gadoxetic acid–enhanced liver MR imaging: a conventional protocol (a fixed scan delay and 2-mL/s injection) using a standard 3-T MR system (Trio-Tim; Siemens, commercialized since 2005) (group A), an optimized protocol (bolus tracking and 1-mL/s injection) using a standard 3-T MR (group B), an optimized protocol using a new 3-T MR (Skyra; Siemens, commercialized since 2012) (group C), and an optimized protocol with CAIPIRINHA using a new 3-T MR (group D). The image quality of the hepatic arterial phase was graded using a 4-point rating scale from 1 (no artifacts) to 4 points (non–diagnostic images with severe artifacts). The differences in image quality scores among the 4 groups were evaluated. In addition, the detection rates of hypervascular hepatocellular carcinomas among the 4 groups were evaluated. ResultsScores of 4 points were observed in groups A (n = 7), B (n = 5), and C (n = 3) but not in group D. The median image quality score was 2 in groups A and B and 1 in groups C and D. From group A to group D, the median image quality score decreased significantly (P = 0.0001). The median image quality score was significantly lower in group D than in groups A and B (P = 0.0001 and 0.001, respectively), whereas there was no significant difference observed between groups C and D (P = 0.656). The detection rates of hypervascular hepatocellular carcinomas on the hepatic arterial phase were not significantly different among the groups (all P > 0.03), except between groups A and D (P = 0.007). ConclusionsThe CAIPIRINHA technique improved the image quality of hepatic arterial phase imaging with gadoxetic acid, reducing the number of non–diagnostic arterial phase studies.

[1]  Joon Koo Han,et al.  Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for Differentiating Small Hepatocellular Carcinomas (≤2 cm in Diameter) From Arterial Enhancing Pseudolesions: Special Emphasis on Hepatobiliary Phase Imaging , 2010, Investigative radiology.

[2]  Elaine M. Caoili,et al.  Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. , 2013, Radiology.

[3]  N. Rofsky,et al.  Shortening MR image acquisition time for volumetric interpolated breath-hold examination with a recently developed parallel imaging reconstruction technique: clinical feasibility. , 2004, Radiology.

[4]  Elmar M Merkle,et al.  Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. , 2010, AJR. American journal of roentgenology.

[5]  Nicole Seiberlich,et al.  Parallel MR imaging , 2012, Journal of magnetic resonance imaging : JMRI.

[6]  Peter Hunold,et al.  Parallel acquisition techniques for accelerated volumetric interpolated breath‐hold examination magnetic resonance imaging of the upper abdomen: Assessment of image quality and lesion conspicuity , 2005, Journal of magnetic resonance imaging : JMRI.

[7]  Berthold Kiefer,et al.  Clinical application of controlled aliasing in parallel imaging results in a higher acceleration (CAIPIRINHA)‐volumetric interpolated breathhold (VIBE) sequence for gadoxetic acid‐enhanced liver MR imaging , 2013, Journal of magnetic resonance imaging : JMRI.

[8]  Robin M Heidemann,et al.  Controlled aliasing in volumetric parallel imaging (2D CAIPIRINHA) , 2006, Magnetic resonance in medicine.

[9]  E. Merkle,et al.  Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. , 2010, AJR. American journal of roentgenology.

[10]  U. Motosugi,et al.  Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifacts on gadoxetic acid‐DTPA (Gd‐EOB‐DTPA)‐enhanced hepatic MR imaging? , 2010, Journal of magnetic resonance imaging : JMRI.

[11]  Geoffrey E. Wile,et al.  Magnetic resonance imaging of the liver: sequence optimization and artifacts. , 2010, Magnetic resonance imaging clinics of North America.

[12]  Ulrike I Attenberger,et al.  Highly Accelerated T1-Weighted Abdominal Imaging Using 2-Dimensional Controlled Aliasing in Parallel Imaging Results in Higher Acceleration: A Comparison With Generalized Autocalibrating Partially Parallel Acquisitions Parallel Imaging , 2013, Investigative radiology.

[13]  O. Dietrich,et al.  High‐resolution renal MRA: Comparison of image quality and vessel depiction with different parallel imaging acceleration factors , 2006, Journal of magnetic resonance imaging : JMRI.

[14]  M. Reiser,et al.  Optimization of the dynamic, Gd-EOB-DTPA-enhanced MRI of the liver: the effect of the injection rate , 2012, Acta radiologica.

[15]  A. Tanimoto,et al.  Reduction of ringing artifacts in the arterial phase of gadoxetic acid-enhanced dynamic MR imaging. , 2012, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[16]  S. Schoenberg,et al.  CAIPIRINHA-Dixon-TWIST (CDT)–Volume-Interpolated Breath-Hold Examination (VIBE): A New Technique for Fast Time-Resolved Dynamic 3-Dimensional Imaging of the Abdomen With High Spatial Resolution , 2013, Investigative radiology.

[17]  U. Motosugi,et al.  Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd‐EOB‐DTPA)‐enhanced magnetic resonance imaging (MRI) , 2009, Journal of magnetic resonance imaging : JMRI.

[18]  C. Sirlin,et al.  Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.